archived M184V/I突变对转换至EVG/C/FTC/TAF方案疗效的影响
这项回顾性多中心研究纳入病毒抑制的HIV感染者,比较有 archived M184V/I突变者(100例)与无突变对照(400例)转换至EVG/C/FTC/TAF后48周病毒学非成功率。结果显示两组非成功率分别为5.0%和3.3%(差异1.7%,95%CI -2.9%-6.3%),K65R或TAMs与病毒学无应答无关。结论认为尽管存在M184V/I突变,EVG/C/FTC/TAF仍能有效维持病毒抑制。
要点
- archived M184V/I突变者转换至EVG/C/FTC/TAF后48周病毒学非成功率为5.0%。
- 无M184V/I突变对照组的病毒学非成功率为3.3%,组间差异无统计学意义。
- 合并K65R或TAMs并未增加病毒学无应答风险。
核心结论
- 在病毒抑制的HIV感染者中,即使存在 archived M184V/I突变(伴或不伴TAMs),转换至EVG/C/FTC/TAF后48周仍能有效维持病毒抑制。
研究设计与样本
- 回顾性多中心研究,纳入已实现病毒抑制(血浆HIV RNA<200 copies/mL)至少6个月的HIV感染者,转换至EVG/C/FTC/TAF。
- 有 archived M184V/I突变者为病例组(100例),按1:4匹配无M184V/I突变对照(400例),匹配因素包括性别、年龄和TDF累积暴露时长。
- 排除有病毒学失败史或对EVG耐药的患者。
主要发现
- 病例组中6例(6.0%)合并K65R,13例(13.0%)合并至少一种TAM。
- 第48周病毒学非成功率(血浆HIV RNA≥50 copies/mL)病例组为5.0%(5/100),对照组为3.3%(13/400),差异1.7%(95%CI -2.9%-6.3%)。
- 病毒学成功率病例组为88.0%,对照组为89.5%。
- K65R突变或TAMs的存在与病毒学无应答无关。
临床怎么用
- 对于病毒已抑制且存在 archived M184V/I突变的HIV感染者,可考虑转换至EVG/C/FTC/TAF方案。
- 转换前需排除病毒学失败史或对EVG耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Real-world experience regarding the effectiveness of co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/C/FTC/TAF) as a switch regimen is sparse among people living with HIV (PLWH) harbouring the M184V/I mutation with or without thymidine analogue-associated mutations (TAMs). METHODS: In this retrospective multicentre study, PLWH who were switched to EVG/C/FTC/TAF after having achieved viral suppression (plasma HIV RNA <200 copies/mL) for 6 months or longer were included. Patients with archived M184V/I mutation (case patients) were matched to controls without M184V/I mutation at a 1:4 ratio. Patients with a history of virological failure or resistance to elvitegravir were excluded. The primary endpoint was virological non-success (plasma HIV RNA ≥50 copies/mL) at Week 48 of switch using a modified FDA snapshot analysis. RESULTS: Overall, 100 case patients with the M184V/I mutation were identified, including 6 (6.0%) with K65R and 13 (13.0%) with at least one TAM, and were matched to 400 controls in terms of gender, age (mean = 40.3 versus 39.7 years) and cumulative exposure duration to tenofovir disoproxil fumarate (median = 146 versus 143 weeks). At Week 48, the rate of virological non-success for the case patients and controls was 5.0% (5/100) and 3.3% (13/400), respectively (difference = 1.7%; 95% CI = -2.9%-6.3%), while the rate of virological success was 88.0% and 89.5% for the case patients and controls, respectively. The presence of the K65R mutation or TAMs was not associated with virological non-response. CONCLUSIONS: Among virally suppressed PLWH, EVG/C/FTC/TAF is effective in maintaining viral suppression at Week 48 despite archived M184V/I mutation with or without TAMs.
引用
- Chen GJ, Lee YL, Lee CH, et al. Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV. J Antimicrob Chemother. 2020. PMID: 32737511. doi:10.1093/jac/dkaa287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。